motexafin-lutetium has been researched along with Brain-Neoplasms* in 2 studies
1 trial(s) available for motexafin-lutetium and Brain-Neoplasms
Article | Year |
---|---|
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Motexafin gadolinium is a magnetic resonance imaging (MRI)--detectable redox active drug that localizes selectively in tumor cells and enhances the effect of radiation therapy. This phase Ib/II trial of motexafin gadolinium, administered concurrently with 30 Gy in 10 fractions whole-brain radiation therapy (WBRT), was conducted to determine maximum-tolerated dose (MTD), dose-limiting toxicity, pharmacokinetics, and biolocalization in patients with brain metastases. Additional endpoints were radiologic response rate and survival.. Motexafin gadolinium was administered before each radiation treatment in this open-label, multicenter, international trial. In phase Ib, drug dose was escalated until the MTD was exceeded. In phase II, drug was evaluated in a narrow dose range.. In phase Ib, the motexafin gadolinium dose was escalated in 39 patients (0.3 mg/kg to 8.4 mg/kg). In phase II, 22 patients received 5 mg/kg to 6.3 mg/kg motexafin gadolinium. Ten once-daily treatments were well tolerated. The MTD was 6.3 mg/kg, with dose-limiting reversible liver toxicity. Motexafin gadolinium's tumor selectivity was established using MRI. The radiologic response rate was 72% in phase II. Median survival was 4.7 months for all patients, 5.4 months for recursive partitioning analysis (RPA) class 2 patients, and 3.8 months for RPA class 3 patients. One-year actuarial survival for all patients was 25%.. Motexafin gadolinium was well tolerated at doses up to 6.3 mg/kg, was selectively accumulated in tumors, and, when combined with WBRT of 30 Gy in 10 fractions, was associated with a high radiologic response rate. Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Female; France; Humans; Male; Maximum Tolerated Dose; Metalloporphyrins; Middle Aged; Photosensitizing Agents; Prospective Studies; ROC Curve; Survival Rate; Tissue Distribution | 2001 |
1 other study(ies) available for motexafin-lutetium and Brain-Neoplasms
Article | Year |
---|---|
Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Gadolinium; Humans; Lutetium; Metalloporphyrins; Photosensitizing Agents | 1999 |